 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > CEL-SCI Corporation
 |
CEL-SCI Corporation |
 |
 |
 |
PROFILE |
 |
CEL-SCI is working on immunotherapy drugs for cancer patients and vaccines to prevent AIDS. The company's Multikine -- made through a proprietary cell-culture technique -- is being tested to treat head and neck cancer, prostate cancer, and HIV. CEL-SCI's T cell modulation technology, called LEAPS, may lead to synthetic vaccines for AIDS, prostate and breast cancer, and herpes. The firm halted development of its HGP-30 AIDS vaccine, which would have treated the form of HIV most prevalent in Africa. CEL-SCI collaborates with institutions like The Johns Hopkins University and Northeastern Ohio University to fund research and development of its products, all of which are in clinical tests in the US and other regions.
COMPETITION |
 |
Chiron Corporation (CHIR)
Introgen Therapeutics, Inc. (INGN)
Progenics Pharmaceuticals, Inc. (PGNX)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: September
2000 Sales (mil.): 0.40
1-Yr. Sales Growth: 0.0%
Employees: 32
Revenue per employee: $12,500.00
KEY PEOPLE |
 |
Geert R. Kersten
CEO
Geert R. Kersten
CFO
CONTACT INFO |
 |
8229 Boone Blvd., Ste. 802
Vienna, VA 22182
US
Phone: 703-506-9460
Fax: 703-506-9471
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |